2015
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics And Clinical Risk Management 2015, Volume 11: 95-105. PMID: 25609974, PMCID: PMC4298300, DOI: 10.2147/tcrm.s32193.Peer-Reviewed Original ResearchPainful diabetic neuropathyDiabetic neuropathyOpioid-based therapyCancer-related painDiabetic neuropathic painChronic pain conditionsGastrointestinal side effectsNorepinephrine reuptake inhibitorsΜ-opioid agonistMechanism of actionNeuropathic painPain conditionsReuptake inhibitorsBack painArthritic painClinical efficacyEffective medicationsClinical studiesSide effectsPainTapentadolNeuropathyOne-thirdMedicationsDiabetes
2013
Patient considerations in the use of tapentadol for moderate to severe pain
Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthcare And Patient Safety 2013, Volume 5: 151-159. PMID: 23861601, PMCID: PMC3704302, DOI: 10.2147/dhps.s28829.Peer-Reviewed Original ResearchTapentadol ERTapentadol IRSevere painChronic painOpioid agonistsClinical trialsSide effectsChronic painful diabetic neuropathyMu-opioid receptor agonistCentral nervous system depressantsSimilar pain reliefTraditional opioid agonistsUncontrolled postoperative painSevere acute painSevere chronic painGastrointestinal adverse effectsPainful diabetic neuropathyCommon side effectsNorepinephrine reuptake inhibitorsPost-surgical patientsOpioid receptor agonistsUse of tapentadolDrug Administration approvalMonoamine oxidase inhibitorsPotent opioid agonist